Personalis, Inc. (NASDAQ:PSNL – Get Free Report) SVP Stephen Moore sold 2,068 shares of the company’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $33,542.96. Following the completion of the sale, the senior vice president directly owned 90,257 shares in the company, valued at $1,463,968.54. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Personalis Price Performance
NASDAQ:PSNL traded up $0.12 during mid-day trading on Tuesday, reaching $16.36. The stock had a trading volume of 1,369,078 shares, compared to its average volume of 2,690,633. The stock’s 50 day simple moving average is $15.06 and its two-hundred day simple moving average is $10.89. Personalis, Inc. has a 1-year low of $4.95 and a 1-year high of $18.89. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of -15.01 and a beta of 2.31.
Personalis (NASDAQ:PSNL – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The firm had revenue of $22.36 million during the quarter, compared to the consensus estimate of $16.69 million. Sell-side analysts anticipate that Personalis, Inc. will post -1.07 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
View Our Latest Analysis on Personalis
Institutional Investors Weigh In On Personalis
A number of large investors have recently added to or reduced their stakes in PSNL. Caitong International Asset Management Co. Ltd boosted its holdings in Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after acquiring an additional 1,479 shares during the period. Quantbot Technologies LP acquired a new position in Personalis in the 2nd quarter valued at approximately $69,000. Jasper Ridge Partners L.P. bought a new stake in shares of Personalis in the 2nd quarter worth approximately $193,000. AXQ Capital LP bought a new stake in shares of Personalis in the 4th quarter worth approximately $119,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Personalis during the 2nd quarter worth approximately $201,000. Institutional investors own 61.91% of the company’s stock.
Personalis Company Profile
Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.
Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.
Featured Stories
- Five stocks we like better than Personalis
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.
